Since 2000, drug companies have paid out $2 billion to settle claims of fraudulent Medicaid-related marketing and pricing practices. Factoring in other fines and penalties, the dollar total rises to more than $3.5 billion--the vast bulk of all the monies paid out under the US False Claims Act. From 2000 to January 2004, eight of the top ten cases resolved under the False Claims Act, which encourages whistleblowers by allowing private citizens to sue on behalf of the government and receive a share of any awards, involved companies in the health care space.
The result is an industry whose marketing practices are in flux, as it tries to determine the kinds of packages...


